U.S. Markets closed

Protalix receives marketing authorization for Elelyso from Israel

Protalix BioTherapeutics (PLX) has received marketing authorization from the Israeli Ministry of Health for Elelyso for injection, an enzyme replacement therapy for the long-term treatment of adults with Type 1 Gaucher disease. Elelyso will be marketed in Israel by Protalix Ltd., the holder of all marketing rights to Elelyso in the Israeli market.This is the second marketing approval of Elelyso, which was approved by the U.S. Food and Drug Administration on May 1, 2012. Marketing applications have been filed in additional territories. Elelyso is marketed in the United States by the Company's commercialization partner, Pfizer (PFE).